Abstract
A lipase-triggered drug release nanoplatform (PGL-DPP-FLU NPs) for multi-modal antifungal therapy is developed. The lipases secreted by C. albicans can accelerate FLU release. The ROS and heat produced by PGL-DPP-FLU NPs make C. albicans more vulnerable to FLU, thereby PGL-DPP-FLU NPs exhibit high performance for combating azole-resistant C. albicans biofilms and wound infection.
MeSH terms
-
Animals
-
Antifungal Agents / chemistry
-
Antifungal Agents / pharmacology*
-
Antifungal Agents / therapeutic use
-
Azoles / chemistry*
-
Azoles / pharmacology
-
Candida albicans / drug effects*
-
Candidiasis / drug therapy
-
Candidiasis / pathology
-
Candidiasis / veterinary
-
Drug Resistance, Fungal / drug effects
-
Ethylene Glycols / chemistry
-
Fluconazole / chemistry
-
Ketones / chemistry
-
Lasers
-
Lipase / metabolism*
-
Mice
-
Nanoparticles / chemistry*
-
Photochemotherapy
-
Phototherapy
-
Polyesters / chemistry
-
Pyrroles / chemistry
Substances
-
Antifungal Agents
-
Azoles
-
Ethylene Glycols
-
Ketones
-
Polyesters
-
Pyrroles
-
diketopyrrolopyrrole dye
-
poly(epsilon-caprolactone)-b-poly(ethylene glycol)
-
Fluconazole
-
Lipase